Dorman Products (DORM) Misses Q1 EPS by 7c

Dorman Products (NASDAQ: DORM) reported Q1 EPS of $0.96, $0.07 worse than the analyst estimate of $1.03. Revenue for the quarter came in at $227.3 million versus the consensus estimate of $234 million.

The Company re-iterated 2018 net sales growth between 6%-9% and expects diluted EPS of between $4.00 and $4.23 on a GAAP basis and Adjusted diluted EPS of between $4.10 and $4.32, or between a 22% and 28% growth rate.

For earnings history and earnings-related data on Dorman Products (DORM) click here.

You May Also Be Interested In

• Freedom Broker Downgrades Dorman Products (DORM) to Hold
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c